The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives
Open accessAbstract
The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of the innate immune cells providing antitumor cytotoxicity activated by antibodies linked to target cells. Natural killer (NK) cells are a small set of lymphocytes, but are considered the most important cells among those able to induce ADCC. They provoke innate immune responses and harmonise spontaneous cytotoxicity towards tumor and virus-infected cells. They are able to swiftly produce biochemical signals and cytokines so as to stimulate subsequent adaptive immune responses. Immunotherapeutics that target NK cells, augmenting their immune response, can cause the antitumor dynamics of the antibodies to be improved. The recent developments in the field of NK cell immunotherapy and genotypic factors which might affect patient responses to antibody-dependent immunotherapies are the main subject of this review, with a particular focus on the manipulations and strategies used to augment ADCC. In the next years combined treatment with monoclonal antibodies (mAbs) and immunomodulatory drugs will be an important part in antitumor therapy. The main challenge remains the difficulty in distinguishing in the clinical setting, between the target effect that many mAbs exert against specific cell membrane receptors and the ADCC effect that they too also can induce. Drugs able to activate NK cells, that are major actors in mAb-mediated ADCC, will improve the ADCC effect against tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Adaptive immune features of natural killer cells
Sun, J. C., Beilke, J. N., & Lanier, L. L. (2009) · Nature · doi:10.1038/nature07665 · Cited by 1,619
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
T cell– and B cell–independent adaptive immunity mediated by natural killer cells
O'Leary, J. G., Goodarzi, M., Drayton, D. L., & von Andrian, U. H. (2006) · Nature Immunology · doi:10.1038/ni1332 · Cited by 919
Cytokine-induced memory-like natural killer cells
Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., & Yokoyama, W. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813192106 · Cited by 831
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
CD27 is required for generation and long-term maintenance of T cell immunity
Hendriks, J., Gravestein, L. A., Tesselaar, K., van Lier, R. A. W., Schumacher, T. N. M., & Borst, J. (2000) · Nature Immunology · doi:10.1038/80877 · Cited by 779
Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., & Caligiuri, M. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4511 · Cited by 652
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425397 · Cited by 552
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
Caligiuri, M. A., Zmuidzinas, A., Manley, T. J., Levine, H., Smith, K. A., & Ritz, J. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1509 · Cited by 435
Natural killer cell biology: An update and future directions
Campbell, K. S., & Hasegawa, J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.006 · Cited by 416
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 415
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
Carrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., Ratto, G. B., Mingari, M. C., Moretta, L., & Ferlazzo, G. (2008) · Cancer · doi:10.1002/cncr.23239 · Cited by 379
Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection
Kelly, J. M., Darcy, P. K., Markby, J. L., Godfrey, D. I., Takeda, K., Yagita, H., & Smyth, M. J. (2002) · Nature Immunology · doi:10.1038/ni746 · Cited by 356
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Human natural killer cell deficiencies and susceptibility to infection
Orange, J. S. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(02)00038-2 · Cited by 338
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 272
Benson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
Molling, J. W., Langius, J. A. E., Langendijk, J. A., Leemans, C. R., Bontkes, H. J., van der Vliet, H. J. J., von Blomberg, B. M. E., Scheper, R. J., & van den Eertwegh, A. J. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5787 · Cited by 205
Petricevic, B., Laengle, J., Singer, J., Sachet, M., Fazekas, J., Steger, G., Bartsch, R., Jensen-Jarolim, E., & Bergmann, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-307 · Cited by 192
Ferris, R. L., Lenz, H.-J., Trotta, A. M., García-Foncillas, J., Schulten, J., Audhuy, F., Merlano, M., & Milano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.008 · Cited by 190
Self-citationClinical Cancer Therapy by NK Cells via Antibody‐Dependent Cell‐Mediated Cytotoxicity
Alderson, K. L., & Sondel, P. M. (2011) · BioMed Research International · doi:10.1155/2011/379123 · Cited by 188
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Beano, A., Signorino, E., Evangelista, A., Brusa, D., Mistrangelo, M., Polimeni, M. A., Spadi, R., Donadio, M., Ciuffreda, L., & Matera, L. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-25 · Cited by 178
Targeting EGFR in Colorectal Cancer
Messersmith, W. A., & Ahnen, D. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0806778 · Cited by 156
Modulation of GITR for cancer immunotherapy
Schaer, D., Murphy, J. T., & Wolchok, J. D. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.011 · Cited by 147
Grzywacz, B. J., Kataria, N., & Verneris, M. R. (2007) · Leukemia · doi:10.1038/sj.leu.2404499 · Cited by 147
Characterization of tumor infiltrating Natural Killer cell subset
Levi, I., Amsalem, H., Nissan, A., Darash‐Yahana, M., Peretz, T., Mandelboim, O., & Rachmilewitz, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3453 · Cited by 136
Reusch, U., Duell, J., Ellwanger, K., Herbrecht, C., Knackmuss, S. H. J., Fucek, I., Eser, M., McAleese, F., Molkenthin, V., Gall, F. L., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1029216 · Cited by 134
Colorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131
Lin, W., Voskens, C., Zhang, X., Schindler, D. G., Wood, A., Burch, E. E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 121
Promising systemic immunotherapies in head and neck squamous cell carcinoma
Gildener‐Leapman, N., Ferris, R. L., & Bauman, J. E. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.009 · Cited by 117
Ortaldo, J. R., Woodhouse, C. S., Morgan, A. C., Herberman, R. B., Cheresh, D. A., & Reisfeld, R. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3566 · Cited by 114
Combination Strategies to Enhance Antitumor ADCC
Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 111
Baltz, K. M., Krusch, M., Bringmann, A., Brossart, P., Mayer, F., Kloss, M., Baessler, T., Kumbier, I., Peterfi, A., Kupka, S., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7724com · Cited by 99
Liu, Q., Sun, Y., Rihn, S. J., Nolting, A., Tsoukas, P. N., Jost, S., Cohen, K. W., Walker, B. D., & Alter, G. (2009) · Journal of Virology · doi:10.1128/jvi.02666-08 · Cited by 94
Lundqvist, A., Yokoyama, H., Smith, A. L., Berg, M., & Childs, R. W. (2009) · Blood · doi:10.1182/blood-2008-11-190421 · Cited by 91
Natural killer cells: a review of manufacturing and clinical utility
Koepsell, S. A., Miller, J. S., & McKenna, D. H. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03724.x · Cited by 88
Maréchal, R., Schutter, J. D., Nagy, N., Demetter, P., Lemmers, A., Deviere, J. M. E., Salmon, I. J., Tejpar, S., & Laethem, J. V. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-340 · Cited by 82
Trial Watch: Immunotherapy plus radiation therapy for oncological indications
Vacchelli, E., Bloy, N., Aranda, F., Buqué, A., Cremer, I., Demaria, S., Eggermont, A. M. M., Formenti, S. C., Fridman, W. H., Fucikova, J. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214790 · Cited by 76
Impact of Stromal Sensitivity on Radiation Response of Tumors
Budach, W., Taghian, A. G., Freeman, J., Gioioso, D., & Suit, H. D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.988 · Cited by 72
Placke, T., Kopp, H., & Salih, H. R. (2010) · Journal of Immunology Research · doi:10.1155/2010/239083 · Cited by 70
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Nigro, C. L., Ricci, V., Vivenza, D., Granetto, C., Fabozzi, T., Miraglio, E., & Merlano, M. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6944 · Cited by 70
Self-citationSchmohl, J. U., Felices, M., Todhunter, D., Taras, E. P., Miller, J. S., & Vallera, D. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12073 · Cited by 70
Seo, Y., Ishii, Y., Ochiai, H., Fukuda, K., Akimoto, S., Hayashida, T., Okabayashi, K., Tsuruta, M., Hasegawa, H., & Kitagawa, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3077 · Cited by 67
Re: Impact of Stromal Sensitivity on Radiation Response of Tumors
Budach, W. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1842 · Cited by 67
PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
Guo, Y., Feng, X., Jiang, Y. Z., Shi, X., Xing, X., Liu, X., Li, N., Fadeel, B., & Zheng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10235 · Cited by 64
Michaud, H., Eliaou, J., Lafont, V., Bonnefoy, N., & Gros, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955684 · Cited by 63
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
Kohrt, H. E. K., Rajasekaran, N., Chester, C., Yonezawa, A., & Zhao, X. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61292 · Cited by 60
Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies
Shevtsov, M. A., & Multhoff, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00492 · Cited by 57
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer
Mimura, K., Kamiya, T., Shiraishi, K., Kua, L., Shabbir, A., So, J. B. Y., Yong, W. P., Suzuki, Y., Yoshimoto, Y., Nakano, T., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28780 · Cited by 56
Monnet, C., Jorieux, S., Souyris, N., Zaki, O., Jacquet, A., Fournier, N., Crozet, F., de Romeuf, C., Bouayadi, K., Urbain, R., et al. (2014) · mAbs · doi:10.4161/mabs.27854 · Cited by 54
Lattanzio, L., Denaro, N., Vivenza, D., Varamo, C., Strola, G., Fortunato, M., Chamorey, E., Comino, A., Monteverde, M., Nigro, C. L., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1960-8 · Cited by 52
Self-citationKlingemann, H., Grodman, C., Cutler, E., Duque, M., Kadidlo, D. M., Klein, A., Sprague, K. A., Miller, K. B., Comenzo, R., Kewalramani, T., et al. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03764.x · Cited by 46
Ibrutinib for the Treatment of Mantle Cell Lymphoma
Herrera, A. F., & Jacobsen, E. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0010 · Cited by 46
Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?
Eccles, S. A. (2001) · Breast Cancer Research · doi:10.1186/bcr276 · Cited by 39
Kasper, S., Breitenbuecher, F., Reis, H., Brandau, S., Worm, K., Köhler, J., Paul, A., Trarbach, T., Schmid, K. W., & Schuler, M. (2013) · Oncogene · doi:10.1038/onc.2012.302 · Cited by 35
Koehn, T. A., Trimble, L. L., Alderson, K. L., Erbe, A. K., McDowell, K. A., Grzywacz, B. J., Hank, J. A., & Sondel, P. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00091 · Cited by 35
Bertino, E. M., McMichael, E. L., Mo, X. M., Trikha, P., Davis, M. E., Paul, B. K., Grever, M. R., Carson, W. E., & Otterson, G. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0879 · Cited by 32
Nigro, C. L., Ricci, V., Vivenza, D., Monteverde, M., Strola, G., Lucio, F., Tonissi, F., Miraglio, E., Granetto, C., Fortunato, M., et al. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i2.222 · Cited by 28
Self-citationSchultz, K. R., Klarnet, J. P., Peace, D. J., et al. (1990) · PubMed · Cited by 23
Three major uncertainties in the antibody therapy of cancer
Stevenson, G. T. (2014) · Haematologica · doi:10.3324/haematol.2013.084640 · Cited by 20
Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice
Macagno, M., Bandini, S., Stramucci, L., Quaglino, E., Conti, L., Balmas, E., Smyth, M. J., Lollini, P., Musiani, P., Forni, G., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301248 · Cited by 19
Self-citationDe Novo Resistance Biomarkers to Anti-Her2 Therapies in Her2-Positive Breast Cancer
Madrid-Paredes, A., Cañadas‐Garre, M., Sánchez–Pozo, A., & Calleja‐Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.88 · Cited by 13
Cited by
LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions
Zhao, P., Xu, Y., Jiang, L.-L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.-J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00550-y · Cited by 54
Metadata
- Authors
- Lo Nigro, C., Macagno, M., Sangiolo, D., Bertolaccini, L., Aglietta, M., & Merlano, M. C.
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2019-03
- Volume
- 7
- Issue
- 5
- Pages
- 105-105
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- OpenAlex
- W2913250085
- Cited by
- 268
- References
- 81
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.